Company Encyclopedia
View More
name
YISHENG PHARM
002566.SZ
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprising acai collagen solid drinks, multivitamin mineral tablets, collagen peptide juice drinks, and fruit lemon powder. It is also involved in pharmaceutical contract manufacturing; production of health food, food, health care products, special medicine purpose formula, fertilizers, beverages, and Chinese herbal medicine extracts; sale of food through the Internet; planting of Chinese herbal medicine extracts; wholesale and retail of cosmetics; road freight transportation; research and development of biological organic; non-residential real estate, machinery, and equipment leasing; packaging printing; paper cutting and sales; technology development, promotion, and application; and the traditional spice products business. In addition, the company provides life beauty services; Chinese medicine health care services; and technical development, consulting, exchange, and transfer services.
3.157 T
002566.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking167/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.82%C
    • Profit Margin6.31%B
    • Gross Margin75.03%A
  • Growth ScoreD
    • Revenue YoY-9.74%D
    • Net Profit YoY-44.06%D
    • Total Assets YoY-0.71%D
    • Net Assets YoY0.37%C
  • Cash ScoreC
    • Cash Flow Margin1583.92%B
    • OCF YoY-9.74%D
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreA
    • Gearing Ratio22.08%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    YISHENG PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 24.13 million yuan, a year-on-year decrease of 32.72%

    According to the Zhitong Finance APP, YISHENG PHARM disclosed its third-quarter report for 2025. The company achieved revenue of 476 million yuan in the first three quarters, a year-on-year decrease of 5.81%; the net profit attributable to the parent company was 24.13 million yuan, a year-on-year decrease of 32.72%; the net profit excluding non-recurring gains and losses was 12.56 million yuan, a year-on-year decrease of 37.81%; the basic earnings per share were 0.0729 yuan

    Zhitong·
    SZ
    002566
    -2.21%
    Zhitong·
    SZ
    002566
    -2.21%

    YISHENG PHARM General Manager Xue Xiaomin plans to reduce holdings of no more than 416,200 shares

    According to the Zhitong Finance APP, YISHENG PHARM announced that the company's general manager, Mr. Xue Xiaomin, holds 1.6647 million shares of the company (accounting for 0.5030% of the total share capital) and plans to reduce his holdings by no more than 416,200 shares (accounting for 0.1258% of the total share capital) through centralized bidding within three months after 15 trading days from the date of the announcement

    Zhitong·
    SZ
    002566
    -2.21%
    Zhitong·
    SZ
    002566
    -2.21%

    YISHENG PHARM released its first-quarter performance, with a net profit attributable to the parent company of 11.8616 million yuan, a decrease of 43.56%

    YISHENG PHARM released its Q1 2025 performance, with operating revenue of 159 million yuan, a year-on-year decrease of 20.59%; net profit attributable to the parent company of 11.8616 million yuan, a year-on-year decline of 43.56%; net profit excluding non-recurring gains and losses of 8.4386 million yuan, a year-on-year decrease of 53.36%; basic earnings per share of 0.0358 yuan

    Zhitong·
    SZ
    002566
    -2.21%
    Zhitong·
    SZ
    002566
    -2.21%

    YISHENG PHARM released its 2024 annual performance, with a net profit attributable to the parent company of 52.0861 million yuan, a year-on-year decrease of 45.02%

    YISHENG PHARM released its 2024 annual report, with operating revenue of 668 million yuan, a year-on-year decrease of 21.69%; net profit attributable to the parent company was 52.0861 million yuan, a year-on-year decrease of 45.02%. The net profit after deducting non-recurring gains and losses was 27.0646 million yuan, a year-on-year decrease of 64.33%. The basic earnings per share were 0.1574 yuan, and it plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares to all shareholders

    Zhitong·
    SZ
    002566
    -2.21%
    Zhitong·
    SZ
    002566
    -2.21%

    YISHENG PHARM: Plans to use no more than 100 million yuan of idle self-owned funds to purchase financial products

    YISHENG PHARM announced that the company held a board of directors and supervisory board meeting on March 10, 2025, and approved the proposal to use no more than 100 million yuan of idle self-owned funds to purchase wealth management products. The investment period is 12 months, and the funds can be used on a rolling basis. The wealth management products include stable products issued by financial institutions such as banks, brokerages, and asset management companies

    Zhitong·
    SZ
    002566
    -2.21%
    Zhitong·
    SZ
    002566
    -2.21%
    © 2025 Longbridge｜Disclaimer